{"id":"W4393177493","doi":"10.1016/s2352-3018(23)00300-4","title":"Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study","year":2024,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Mental Health; ViiV Healthcare; International Maternal Pediatric Adolescent AIDS Clinical Trials Network; Gilead Sciences","keywords":"Rilpivirine; Medicine; Pharmacokinetics; Pharmacology; Human immunodeficiency virus (HIV); Dolutegravir; Phases of clinical research; Oncology; Internal medicine; Virology; Antiretroviral therapy; Viral load; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001881213,0.0006935761,0.001234317,0.0004075512,0.0002022509,0.0009945404,0.0006886484,0.001168045,0.00239796],"category_scores_gemma":[0.002346389,0.0005674998,0.001114371,0.0003501586,0.0008776034,0.001069567,0.0002404452,0.002324597,0.0004712979],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008544498,"about_ca_system_score_gemma":0.0007496079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000995782,"about_ca_topic_score_gemma":0.001168417,"domain_scores_codex":[0.9991604,0.0004702325,0.00003479643,0.0001193851,0.0001321267,0.00008316146],"domain_scores_gemma":[0.9983017,0.0005771448,0.0004636492,0.0001482053,0.00009217595,0.0004170165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8153353,0.02507727,0.02408049,0.0006059897,0.002218945,0.0002182887,0.0004300489,0.00138211,0.03367607,0.0002334875,0.001302141,0.09543975],"study_design_scores_gemma":[0.3414523,0.5433458,0.09829513,0.00009252992,0.002446948,0.0006840082,0.0002878249,0.002589925,0.007268176,0.0003934332,0.003025105,0.000118882],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997264,0.001334436,0.0001956729,0.00007184077,0.00002495721,0.000178953,0.0004061246,0.00002086019,0.0005031214],"genre_scores_gemma":[0.9972379,0.0006857439,0.0004424517,0.0001921531,0.00005889889,0.0001536691,0.0005431293,0.00002171666,0.0006643286],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00239796,"threshold_uncertainty_score":0.009948909,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08758692114915416,"score_gpt":0.3874615136163261,"score_spread":0.299874592467172,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}